GMMMG logo

NHS photos

NHS logo


<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during September 2016

September 2016


New Therapies Subgroup


The following New Therapies recommendations were signed off by GMMMG at their September meeting and are now available on the website. Please see links below for details around whether the drugs have been recommended for use or not:

Formulary Subgroup


The following formulary amendments have been approved during August and September:

    - the formulary will reflect TA398 (Lumacaftor-ivacaftor), TA399 (Azacitidine), TA400 (Nivolumab), NG49 (NAFLD), NG50 (Cirrhosis), NG51 (Sepsis) and NG52 (NHL)

    - the formulary will reflect the July and August MHRA DSU with the addition of warnings for warfarin and calciphylaxis, citalopram and cocaine use, and posoconazole.

At the September meeting FSG agreed the following amendments to be made to the formulary in due course:

  • Removal of Dymista from the Grey list and addition to the formulary, for use when a combination product is required (following the revised NTS recommendation)
  • Updates to be made to chapter 1 of the formulary to include additional information relating to H.pylori prescribing.
  • Addition of a note to the dosulepin entry on the DNP list enforcing the restrictions the DNP list places on dosulepin in all cases i.e. licensed and unlicensed uses based on the risk of toxicity in overdose.
  • Addition of sufentanil sublingual tablet system (Zalviso) to the DNP list as per the NTS recommendation
  • Addition of alimemazine to the DNP list; following the recent increase in price of this product, it was assessed for DNP inclusion and deemed not to be a cost effective use of NHS resources
  • Chapter 3 of the formulary will be updated to reflect the recently approved COPD pathway i.e. tiotropium handihaler will be replaced with tiotropium SMI (Respimat), umeclidinium DPI (Incruse Ellipta), Fluticasone/vilanterol (Relvar Ellipta) will be added and indacaterol DPI (Onbrez Breezhaler) will be removed from the formulary. A link to the pathway will also be added.
  • FSG elected interim co-Chairs (Leigh Lord and Claire Vaughan) and a vice chair (Dr Connie Chen), these positions will be held until the subgroups undergo the proposed restructure. FSG expressed their thanks to Charlotte Skitterall and Dr Helen Burgess for their dedication, hard work and enthusiasm during their time as Chair and vice-chair of FSG respectively.

The following work is ongoing:

Development of a GM asthma pathway
GM anal irrigation systems pathway
Swollen leg guideline
RA pathway update
PsA/AS pathway update



The GMMMG declarations of interest policy was updated in line with guidance issued by NHS England and this has now been approved and is available on the website here.


The Ophthalmology Macular Pathway is now available for comment on the GMMMG website:
You may need to refresh (F5) the page if your computer has viewed this page previously to see the updated page.

The pathway is intended for use in patients within the Greater Manchester health economy and we are therefore seeking comments from all Greater Manchester healthcare professionals. The pharmaceutical industry is invited to comment on factual inaccuracies only.

This document has been adapted from the Lancashire Medicines Management Group guideline with their permission.

The consultation period is open until 5pm on Friday October 7th 2016. Please be reminded that ALL comments must be received during the consultation period.

<< Back



RSS Feed